Abbott and AstraZeneca drop Certriad
This article was originally published in Scrip
Executive Summary
Abbott and AstraZeneca are to discontinue their joint collaboration for the development of Certriad (rosuvastatin/fenofibric acid delayed release) for the treatment of mixed dyslipidaemia.